Polycythemia is a condition in which there are too many red blood cells in the blood circulation. Polycythemia may occur with many different conditions. Some of the babies affected by polycythemia include those born after 42 weeks (post-term), small for gestational age (SGA )/intrauterine growth restriction (IUGR ), identical twins who share the same placenta and develop twin to twin transfusion, infants of diabetic mothers, and those with chromosomal abnormalities. Mild polycythemia may not cause problems. However, too many red blood cells can make the blood "viscous', making it harder to circulate through the vessels and to the organs and cause complications.
The accepted treatment of polycythemia is partial exchange transfusion (PET). PET involves slowly removing some of the blood volume and replacing the withdrawn blood with fluids to help dilute the red blood cell concentration.Treatment of polycythemia with PET is controversial. It may be associated with earlier improvement of symptoms.This review of trials found that there is no evidence of long-term benefit from PET in polycythemic infants, but the estimates of these effects are extremely imprecise due to the large number of surviving infants who were not assessed.
Czytaj pełne streszczenie
Wprowadzenie
Hyperviscosity of blood results in increased resistance to blood flow and decreased oxygen delivery. In the neonate, hyperviscosity can cause abnormalities of central nervous system function, hypoglycemia, decreased renal function, cardiorespiratory distress, and coagulation disorders. Hyperviscosity has been reported to be associated with long-term motor and cognitive neurodevelopmental disorders. Blood viscosity exponentially increases when an infant has polycythemia (hematocrit ≥ 65%). Partial exchange transfusion (PET) is traditionally used as the method to lower the hematocrit and treat hyperviscosity.
Cele
To evaluate the effect of PET on mortality and neurodevelopmental outcome in infants with neonatal polycythemia.
Metody wyszukiwania badań
Electronic databases searched included: The Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library), MEDLINE (1966 to October 2009), EMBASE (1980 to October 2009) and CINAHL (1982 to October 2009).
Kryteria doboru badań
Randomized controlled clinical trials or quasi-randomized trials comparing partial exchange transfusion to control (non-treatment) in infants with neonatal polycythemia
Zbieranie i analiza danych
Data collection and analysis was performed according to the standards of the Cochrane Neonatal Review Group.
Główne wyniki
One study (Kumar 2004) reported no demonstrable effect on the risk of neonatal mortality (RR 5.23, 95% CI 0.66, 41.26).
Four studies reported on neurodevelopmental assessment at 18 months or older. The completeness of follow-up differed widely between the studies. Overall, no difference was seen in developmental delay when all trials are analysed based on available cases (typical RR 1.45, 95% CI 0.83 to 2.54) and when only the randomized controlled trials are analysed (typical RR 1.35, 95% CI 0.68 to 2.69). A best case/worst case analysis of developmental delay is consistent with large benefit or harm from PET.
Two studies reported on necrotizing enterocolitis (Van der Elst 1980; Black 1985). An increase in the risk of NEC was noted in infants receiving PET (typical RR 11.18, 95% CI 1.49, 83.64; typical RD 0.14, 95% CI 0.05, 0.22). No differences in short-term complications including hypoglycemia (two studies) and thrombocytopenia (one study) were noted.
Wnioski autorów
There are no proven clinically significant short or long-term benefits of PET in polycythemic newborn infants who are clinically well or who have minor symptoms related to hyperviscosity. PET may lead to an increase in the risk of NEC. The data regarding developmental follow-up are extremely imprecise due to the large number of surviving infants who were not assessed and, therefore, the true risks and benefits of PET are unclear.
